Techsomed Ltd., a pioneer in medical software focusing on enhancing the clinical impact of ablation therapy, has announced that it has secured 510(k) clearance from the USA Food and Drug Administration (FDA) for its software, VisAble.IO. This software is designed to aid physicians in planning liver ablation procedures and verifying ablation zones, aiming to enhance treatment accuracy.
Ablation Therapy, a favored minimally invasive treatment, uses extreme temperatures to eliminate abnormal tissue. The VisAble.IO software is a component of Techsomed’s comprehensive BioTrace solution, an AI-powered system for Image Guided Ablation Therapy. This system employs AI technology to utilize standard imaging techniques, such as ultrasound, CT, and MRI, to visualize the entire ablation zone in real-time. The software also offers advanced treatment planning and assessment tools, ensuring patients receive optimal care.